{"id":442514,"date":"2026-05-15T04:34:10","date_gmt":"2026-05-15T04:34:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/442514\/"},"modified":"2026-05-15T04:34:10","modified_gmt":"2026-05-15T04:34:10","slug":"assessing-abivax-societe-anonyme-enxtpaabvx-valuation-after-recent-share-price-softness-and-conflicting-metrics","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/442514\/","title":{"rendered":"Assessing ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Valuation After Recent Share Price Softness And Conflicting Metrics"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

Recent performance snapshot and context <\/p>\n

ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) has attracted attention after its stock declined 1.3% over the past day and is down 3.9% over the past week, which has prompted closer scrutiny from investors.<\/p>\n

See our latest analysis for ABIVAX Soci\u00e9t\u00e9 Anonyme.<\/a><\/p>\n

While the stock has eased recently, with share price returns down over the past week and year to date, the very large 1 year total shareholder return highlights how sentiment around ABIVAX Soci\u00e9t\u00e9 Anonyme has shifted sharply over a longer horizon.<\/p>\n

If you are weighing ABIVAX Soci\u00e9t\u00e9 Anonyme against other potential opportunities in healthcare and biotech, it can help to see what is moving across AI driven drug and diagnostics platforms via our 124 healthcare AI stocks<\/a><\/p>\n

With ABIVAX Soci\u00e9t\u00e9 Anonyme posting revenue growth of 55.4% but still reporting a net loss of \u20ac336.102 million and trading below analyst price targets, investors now face a key question: is there genuine upside here or is the market already pricing in future growth?<\/p>\n

Preferred Price to Book of 18x: Is it justified? <\/p>\n

ABIVAX Soci\u00e9t\u00e9 Anonyme is currently trading on a P\/B of 18x, compared with an industry average of 4.6x, which immediately raises valuation questions when set against the last close at \u20ac103.5.<\/p>\n

P\/B compares a company\u2019s market value to its book value, so an 18x multiple means investors are paying a high price relative to the underlying net assets on the balance sheet. For a clinical stage biotech that is still loss making, that usually reflects expectations around future revenue growth and the potential of the pipeline rather than current earnings power.<\/p>\n

Here, the picture is mixed. On one hand, ABIVAX Soci\u00e9t\u00e9 Anonyme is described as trading at 86% below an internal fair value estimate based on future cash flows, and revenue is forecast to grow 55.4% per year, ahead of both the French market and the 20% threshold flagged in the data. On the other hand, the company is currently loss making, is forecast to remain unprofitable over the next 3 years, has a negative return on equity of 73.84%, and relies entirely on higher risk external borrowing for funding, with shareholders having been diluted in the past year.<\/p>\n

Compared with the French Biotechs industry, where the average P\/B is 4.6x, ABIVAX Soci\u00e9t\u00e9 Anonyme looks expensive on this preferred multiple by a wide margin. This suggests the market is pricing in much stronger outcomes than for peers. With no fair ratio available to indicate where the P\/B might sit if it reverted to a level implied by fundamentals, the gap to the sector average stands out even more clearly.<\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n

Result: Price-to-book of 18x (OVERVALUED)<\/p>\n

However, the story can change quickly if the Phase 3 and Phase 2b trials for obefazimod disappoint, or if continued losses force further shareholder dilution.<\/p>\n

Find out about the key risks to this ABIVAX Soci\u00e9t\u00e9 Anonyme narrative.<\/a><\/p>\n

Another view on value: DCF points the other way <\/p>\n

The 18x P\/B ratio suggests ABIVAX Soci\u00e9t\u00e9 Anonyme is expensive compared with peers. However, our DCF model indicates a fair value estimate of \u20ac741.78 per share versus the current \u20ac103.5. On this view, the stock appears deeply undervalued. This raises the question of which signal may be more informative for investors.<\/p>\n

To see how this cash flow based view is constructed and what assumptions underpin it, take a closer look at the SWS DCF model via the Look into how the SWS DCF model arrives at its fair value.<\/a><\/p>\n

\"ABVX<\/a> ABVX Discounted Cash Flow as at May 2026 <\/p>\n

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ABIVAX Soci\u00e9t\u00e9 Anonyme for example<\/a>). We show the entire calculation in full. You can track the result in your watchlist<\/a> or portfolio<\/a> and be alerted when this changes, or use our stock screener to discover 234 high quality undervalued stocks<\/a>. If you save a screener<\/a> we even alert you when new companies match – so you never miss a potential opportunity.<\/p>\n

Next Steps <\/p>\n

With mixed signals on value and sentiment, this is the moment to look at the underlying data yourself and decide how the risk reward trade off stacks up for your portfolio by reviewing the 2 key rewards and 2 important warning signs<\/p>\n

Looking for more investment ideas? <\/p>\n

If you want a fuller view of opportunities beyond ABIVAX Soci\u00e9t\u00e9 Anonyme, broaden your watchlist with targeted stock ideas that match different risk and income goals.<\/p>\n

Target potential mispricings across the market by reviewing the 234 high quality undervalued stocks<\/a> and see which companies currently sit below their implied value.<\/p>\n

Strengthen the income side of your portfolio by scanning for reliable high yield opportunities with the 466 dividend fortresses<\/a> that could complement growth focused holdings.<\/p>\n

Prioritise resilience by zeroing in on companies screened for lower risk profiles using the 302 resilient stocks with low risk scores<\/a> and avoid missing stocks that may better fit your comfort level.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ABVX.PA<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":232133,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,11628,77207,85,46,17582,71114],"class_list":["post-442514","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-fair-value","tag-future-cash-flows","tag-il","tag-israel","tag-revenue-growth","tag-societe-anonyme"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/442514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=442514"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/442514\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/232133"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=442514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=442514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=442514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}